AstraZeneca

D9670C00001 | Destiny-Breast06 (DB-06)

NCT04494425

Pending

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Status:

Opening Soon

26459-200.png

III

Phase

Line of Therapy.png

3rd

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

Trastuzumab Deruxtecan (T-DXd)

Treatment Arms

o Experimental: Trastuzumab deruxtecan

o Active Comparator: Standard of Care